Medication info
Escitalopram Magnesium Trihydrate 20 mg (Esomeprazole Magnesium Trihydrate)

Escitalopram Magnesium Trihydrate 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.3mg / 1 tablet
Manufacturer / importer
Dasan Pharmaceutical Co., Ltd.
Appearance
Light pink round film-coated tablet
Packaging
PTP packaging - 28 tablets/PTP [14 tablets/PTP x2]
Approval status
Active

MFDS item code 201906609 · Approved 2019.09.23 · Insurance code 678601530

Summary

Main use
Treatment of acid-related disorders and prevention of rebleeding, Helicobacter pylori eradication, treatment and prevention of anti-inflammatory drug-induced gastrointestinal disorders
Who uses it
Adults · Children
Adult dosage
Directions for use: Swallow this medicine with a liquid such as water; do not chew or crush. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent symptoms with 20 mg once daily. · In adults, 20 mg once daily may be administered as needed. As-needed administration is not recommended for controlling subsequent symptoms in patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug treatment. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg, twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical studies lasting longer than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses greater than 80 mg daily should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed 20 mg of this medicine. 6. Older adults: No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent symptoms with 20 mg once daily. 3. Children under 12 years: There is no experience with administration of this medicine to children under 12 years of age.

Ingredients

Manufacturer
Dasan Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders and prevention of rebleeding, Helicobacter pylori eradication, treatment and prevention of anti-inflammatory drug-induced gastrointestinal disorders

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
View approved original text

This medication is used to treat gastroesophageal reflux disease, erosive reflux esophagitis and to alleviate symptoms. It also helps treat duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection and prevent their recurrence. It's effective for treating and preventing upper gastrointestinal symptoms and gastric ulcers caused by nonsteroidal anti-inflammatory drugs. It is also applied for the treatment of Zollinger-Ellison syndrome and is used as maintenance therapy after prevention of rebleeding from gastric ulcers or duodenal ulcers. Thus, it is used for the treatment and prevention of complex gastrointestinal disorders.

Dosage and Administration

Adult dosage

Directions for use: Swallow this medicine with a liquid such as water; do not chew or crush. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent symptoms with 20 mg once daily. · In adults, 20 mg once daily may be administered as needed. As-needed administration is not recommended for controlling subsequent symptoms in patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug treatment. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg, twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical studies lasting longer than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses greater than 80 mg daily should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed 20 mg of this medicine. 6. Older adults: No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent symptoms with 20 mg once daily. 3. Children under 12 years: There is no experience with administration of this medicine to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. Individuals who are allergic to this drug, its ingredients, or similar drugs, or have experienced hypersensitivity reactions should avoid taking it. Also, those allergic to certain antibiotics used in combination to eradicate Helicobacter pylori should not use this medication. Patients taking specific cardiac-related medications or with a history of myocardial infarction, as well as nursing women, should also refrain from taking this drug. This medication contains a dye called Yellow No. 4, and individuals allergic to this component should use it with caution. While taking this medication, various side effects may occur. For example, reductions in blood cell counts, allergic reactions, edema, insomnia, headaches, dizziness, abdominal pain, nausea, liver function abnormalities, skin rashes, muscle pain, and other symptoms have been reported. Rarely, serious side effects such as severe skin reactions or muscle damage may occur, and if symptoms appear, immediate consultation with healthcare personnel is required. If taking this medication for a long time, regular examinations are necessary, and it should be administered after accurate diagnosis when gastrointestinal tumors are suspected. Additionally, this drug reduces gastric acid secretion, resulting in an increased risk of bacterial overgrowth in the gastrointestinal tract, so if diarrhea persists, healthcare personnel should be informed. This medication can interact with other drugs, so if there are any other medications being taken, it is essential to inform your doctor or pharmacist. In particular, caution is needed when used concurrently with certain antivirals, antibiotics, and anticoagulants. During pregnancy, the safety of this medication has not been sufficiently established, so it should only be used cautiously when necessary, and it is better to avoid it while nursing. There is no specific antidote in case of overdose, hence treatment should be symptomatic. Store this medication out of reach of children, and it is safer not to transfer it to another container.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, perception abnormalities, drowsiness, dysgeusia, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, xerostomia, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, jaundice, hepatitis, hepatic failure, encephalopathy, dermatitis, itching, rash, urticaria, alopecia, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid enlargement, irritable bowel syndrome, exacerbated constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, vomiting, otitis, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, exacerbated arthritis, arthropathy, convulsions, fibromyalgia syndrome, hernia, rheumatic polymyalgia, arthralgia, loss of appetite, apathy, increased appetite, confusion, worsening depression, muscle spasticity, anxiety, sensory loss, erectile dysfunction, insomnia, migraine, exacerbated migraine, sleep disorders, tremors, dizziness, visual field loss, perception abnormalities, drowsiness, dysmenorrhea, menstrual disorders, vaginitis, exacerbated asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, altered smell, loss of taste, taste changes, abnormal urination, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air or moisture, and the storage temperature should be maintained between 1 to 30 degrees Celsius at room temperature. Proper storage helps maintain the efficacy of the drug for a longer duration.

Appearance and packaging

Appearance

Light pink round film-coated tablet

Package unit

PTP packaging - 28 tablets/PTP [14 tablets/PTP x2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.